Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
personnel change, unable to continue study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control | Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done. | ||
| intervention | Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods | within first 7 days of culture result |
| Measure | Description | Time Frame |
|---|---|---|
| Time (in hours) to identification of MRSA. | within first 3 days of culture result | |
| Vancomycin days of therapy following S. aureus culture result | during the 2 weeks following culture result |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with MSSA infection who are switched from an MRSA-active drug to an MSSA-active drug . | within 48 hours of Gram-stain result | |
| Duration of bacteremia in patients with MSSA or MRSA bloodstream infections | within first 30 days of culture result |
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures between Sept 15, 2012 - Dec 31, 2012 (control) and Sept 15, 2013 - Dec 31, 2013 (intervention)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ritu Banerjee, MD, PhD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
| ID | Term |
|---|---|
| D013203 | Staphylococcal Infections |
| ID | Term |
|---|---|
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Time to contact isolation in patients with MRSA infections | within first 7 days of culture result |
| Length of hospitalization | from time of culture result to hospital discharge, an expected average duration of 4 weeks |
| Total healthcare costs (broken down by bed, laboratory, and pharmacy costs). | participants will be followed for the duration of hospital stay following positive culture result, an expected average of 4 weeks. | from time of culture result to time of hospital discharge, an expected average duration of 4 weeks |
| Proportion of patients where a electronic (P-care) rule flagged for discordant therapy for the PBP2a result | within first 3 days after culture result |
| Proportion of patients where the pharmacist contacted the service to modify therapy | wihtin first 7 days after culture result |